Healthcare Industry News: vascular access
News Release - May 1, 2007
AngioDynamics Expands PTA Balloon Dilatation Catheter Portfolio with Introduction of Profiler(R)QUEENSBURY, N.Y.--(HSMN NewsFeed)--AngioDynamics, Inc. (NASDAQ: ANGO ), today announced the introduction of its Profiler® Balloon Dilatation Catheter in the U.S. market. This new low profile balloon catheter is indicated for general percutaneous transluminal angioplasty (PTA) of the iliac, femoral, and renal arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.
PTA, an alternative to open vascular surgery, is a procedure used to restore blood flow through narrowed arteries that can be caused by congenital factors or as a result of atherosclerotic disease. PTA involves inserting a balloon catheter into a narrow or occluded blood vessel to recanalize and dilate the vessel by inflating the balloon. It is most commonly used to treat narrowing in the leg arteries, and can also be used to treat narrowing in veins.
"The development of low profile PTA balloon technology allows physicians to perform angioplasty in a less-invasive manner, which improves the overall quality of patient care," commented Dr. John Aruny, Associate Professor and Co-Chief, Vascular and Interventional Radiology at Yale University School of Medicine. "This device, with its low profile configuration, is an excellent example of a new technology that limits the size of the introducer sheath to 5F while allowing inflation diameters up to 8mm. The ability to work through smaller sheaths will directly contribute to lessening puncture site morbidity," added Dr. Aruny.
AngioDynamics' Profiler offers a broad range of low profile PTA balloons, with configurations of up to 8mm x 4cm balloons compatible with 5F sheaths, which provide access to small vessels, tortuous anatomy, and tight stenotic lesions. Additionally, the Profiler family offers a line of 9mm and 10mm balloons that are compatible with a 6F sheath.
"The Profiler is an exciting new addition to our PTA product line and fits with AngioDynamics' strategy of providing innovative products that improve patient outcomes, care and comfort," commented Eamonn P. Hobbs, AngioDynamics' president and chief executive officer. "Along with the recent launch of the Smart Port(TM) CT, we continue to build our market opportunity through an increasingly diverse range of technologies."
AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.
The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended June 3, 2006, may affect the actual results achieved by the Company.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.